Recruiting Sarcoma Studies in Ann Arbor
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the pr...
Lurbinectedin in FET-Fused Tumors
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma....
About Sarcoma Clinical Trials in Ann Arbor
Sarcomas are rare cancers that arise in bone and soft tissues including muscle, fat, blood vessels, and connective tissue. There are more than 70 subtypes of sarcoma. Treatment usually involves surgery combined with radiation and/or chemotherapy.
There are currently 2 sarcoma clinical trials recruiting participants in Ann Arbor, MI. These studies are seeking a combined 513 participants. Research is being sponsored by PharmaMar, Children's Hospital of Philadelphia. Clinical trial participation is free and participants receive study-related medical care at no cost.
Sarcoma Clinical Trials in Ann Arbor — FAQ
Are there sarcoma clinical trials in Ann Arbor?
Yes, there are 2 sarcoma clinical trials currently recruiting in Ann Arbor, MI. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Ann Arbor?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.
Are clinical trials in Ann Arbor free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.
What sarcoma treatments are being tested?
The 2 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for sarcoma.
Data updated March 2, 2026 from ClinicalTrials.gov